Business Standard

Sun Pharma at new high on FDA nod for generic version of Januvia

USFDA has granted its subsidiary, two tentative approvals for its ANDA for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Related News

Sun Pharmaceutical Industries has moved higher by 3% to Rs 914, extending its previous day’s 2.3% gain after the company said it has received a tentative approval from the US drug regulator for generic version of Januvia.

The stock opened at Rs 886 and hit a new high of Rs 920 on NSE. The trading volumes on the counter more than doubled with a  combined 699,849 shares changing hands till 1141 hours on NSE and BSE.

On Monday, said that the US Food and Drugs Administration (USFDA) has granted its subsidiary, two tentative approvals for its Abbreviated New Drug Applications (ANDA) for generic version of Januvia, Sitagliptin tablets and generic version of Glumetza, Metformin HCl extended-release tablets.

Sitagliptin tablets have annual sales of approximately US$ 2.7 billion, while Metformin HCl Extended-release tablets have annual sales of approximately US$ 140 million in the US, it added.

Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. Metformin HCl Extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
 

Read more on:   
|
|

Read More

Fresenius Kabi Oncology soars on delisting plan

The promoter intends to pay an indicative price of Rs 130 per share to acquire the shares offered to it in the Delisting Offer

Quick Links

 

Market News

Punj Lloyd up 5% on talk of stake sale in Medanta Medicity

Meanwhile, the board is schedule to meet tomorrow to consider private placement of non convertible debentures, subordinated debt instruments and ...

Soyabean down 1% on weak global cues

Market analysts attributed fall in soyabean prices at futures trade to offloading of positions by speculators, tracking a weak trend overseas

Barley up 1% on low-level buying in spot markets

Marketmen said besides emergence of low-level demand in the spot markets, restricted supplies from growing regions, mainly supported the uptrend

Vikas GlobalOne surges 19% on bonus issue plan

The board will meet on September 17, to consider issue bonus shares to the equity shareholders of the company.

Refined soya oil moves up 0.9% on strong demand

Analysts said fresh positions built-up by speculators on the back of strong demand in spot markets against tight supplies from producing ...

Back to Top